Multimedia
View More
Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In episode 3 of an ongoing series of sharing sessions between a physician and patient, Jordan J. Feld, MD, MPH, and Wendy, who is living with chronic hepatitis B, discuss the challenges of determining the best time to start treatment. The conversation focuses on incorporating shared decision-making, particularly for cases that are not straight forward and do not fit into an one specific category outlined by the guidelines.
Presenter:
Jordan J. Feld, MD, MPH
Associate Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Disease
Sandra Rotman Centre for Global Health
Toronto, Canada
Contact Clinical Care Options
For customer support please email: customersupport@clinicaloptions.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
Top EASL 2021 studies from Clinical Care Options (CCO) and Stefan Zeuzem: HBV Cure, HCV point-of-care testing and treatment cascade, utility of SVR4, emerging HDV treatments
Stefan Zeuzem, MD
Released: July 22, 2021
Robert Gish on cure strategies at EASL 2021: si RNAs, JNJ-3989, AB-729, GSK3228836, VIR-3434, c-PAMs or capsid inhibitors, AB-836, and more from Clinical Care Options (CCO)
Robert G. Gish, MD
Released: July 22, 2021
Commentary from Nancy Reau on HDV and HBV
Nancy Reau, MD
Released: July 22, 2021
Top EASL 2021 studies from Clinical Care Options (CCO) and Tarik Asselah: HBV Cure, HCV point-of-care testing and treatment cascade, utility of SVR4, emerging HDV treatments
Tarik Asselah, MD, PhD
Released: July 20, 2021
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.